Xeljanz
Phase 2Small molecule
PfizerXeljanz is one of 35 small molecule programs targeting Juvenile Idiopathic Arthritis. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Juvenile Idiopathic Arthritis
#DrugCompanyPhaseTrials
1Trexall
Jazz PharmaceuticalsApproved
Humira
NovartisApproved
Arava
SanofiApproved
Azulfidine
PfizerApproved
Aleve
Jazz PharmaceuticalsApproved
Medrol
PfizerApproved
Celebrex
PPhiladelphia Eye Associates
Approved
Anjeso
Boehringer IngelheimApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Granulomatous Disease1 trial
Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
Enrolling by invitation·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05104723·20 enrolled
Arthritis, Juvenile1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Xeljanz. EMBL-EBI & Wellcome Sanger Institute.
- [4]